GGHC
IMNM icon

Gilder Gagnon Howe & Co’s Immunome IMNM Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.23M Sell
152,265
-17,002
-10% -$364K 0.03% 194
2026
Q1 		$3.7M Sell
169,267
-5,594
-3% -$125K 0.04% 165
2025
Q4 		$3.76M Buy
174,861
+41,749
+31% +$733K 0.04% 164
2025
Q3 		$1.56M Buy
+133,112
New +$1.32M 0.02% 202

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Gilder Gagnon Howe & Co's IMNM Position: Q2 2026 in Review

Gilder Gagnon Howe & Co reduced its Immunome (IMNM) stake by 10% in Q2 2026, selling an estimated $364K and leaving 152,265 shares worth $3.23M. The position accounts for 0.03% of the portfolio, ranked #194.

Gilder Gagnon Howe & Co first reported a position in IMNM in Q3 2025 and has held it in 4 quarters since. The position peaked at $3.76M in Q4 2025. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Gilder Gagnon Howe & Co held 152,265 shares of Immunome worth $3.23M as of Q2 2026.
  • Gilder Gagnon Howe & Co sold 17,002 Immunome shares in Q2 2026, an estimated $364K.
  • Immunome made up 0.03% of Gilder Gagnon Howe & Co's portfolio in Q2 2026, its #194 holding.
  • Gilder Gagnon Howe & Co first reported a position in Immunome in Q3 2025 and has held it in 4 quarters since.
  • Gilder Gagnon Howe & Co's Immunome position peaked at $3.76M in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2026, filed 14 Aug 2026.